Contract analysis

I. Executive Summary The purpose of this memorandum is to provide Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") with a comprehensive legal and regulatory analysis of the three promotional materials for Zelvara® (trepivant sodium; NDA 214-837) cited by the United States Food and Drug Administration's ("FDA") Office of Prescription Drug Promotion ("OPDP") in its inquiry letter dated October 12, 2023, whi

1. Digital Banner Ad ZVR-2023-BNR-044 — A digital banner advertisement displayed on MedLinkPro, a healthcare-professional-targeted medical-education platform, from April 15, 2023, through August 31, 2023, which featured the claim "Fastest Onset in Its Class" and omitted hepatotoxicity risk information from the approved Prescribing Information.

2. Physician Email Blast ZVR-2023-EML-019 — A branded email communication sent to approximately 42,000 neurologists and primary-care physicians on June 7, 2023, which included a bar chart presenting SUMMIT-3 pivotal trial efficacy data using a truncated y-axis that visually exaggerated the efficacy differential between Zelvara® and its comparator.

3. Sales Representative Detail Aid ZVR-2023-DA-007 — A printed sales representative detail aid (leave-behind piece) approved on March 22, 2023, which cited an unpublished, company-sponsored retrospective chart review without disclosing Penterra's funding of the study or the absence of a control arm. All three materials were part of the broader "Clarity Campaign," a multi-channel promotional initiative designed and ex

II. Background A. Zelvara® Product Profile Zelvara® (trepivant sodium) is an oral prescription medication available in 75 mg and 150 mg tablet strengths. The drug was approved by the FDA on October 11, 2019, under New Drug Application ("NDA") No. 214-837. The approved indication is for the acute treatment of migraine with or without aura in adults. Zelvara® is not approved for prophylactic (preventive) treatment of m

Section 502(n) of the FDCA (21 U.S.C. § 352(n)). This section establishes the overarching requirement that prescription drug advertisements not be false or misleading in any particular and that they include a "true statement" of information in brief summary relating to side effects, contraindications, and effectiveness of the drug. A drug is deemed to be misbranded if its advertising is false or misleading or fails t

III. Analysis of Material #1: Digital Banner Ad (ZVR-2023-BNR-044) A. Description of the Material The first of the three promotional materials cited in the Inquiry is a digital banner advertisement bearing Material ID ZVR-2023-BNR-044. A copy of this material is attached hereto as Appendix B. The banner ad was designed and produced by Ridgeline Health Analytics LLC under the Clarity Campaign SOW and was displayed on

IV. Analysis of Material #2: Physician Email Blast (ZVR-2023-EML-019) A. Description of the Material The second promotional material cited in the Inquiry is a branded physician email communication bearing Material ID ZVR-2023-EML-019. A copy of this material, including the bar chart at issue, is attached hereto as Appendix C. The email was sent on June 7, 2023, to a distribution list of approximately 42,000 healthcar

V. Analysis of Material #3: Sales Representative Detail Aid (ZVR-2023-DA-007) A. Description of the Material The third promotional material cited in the Inquiry is a printed sales representative detail aid bearing Material ID ZVR-2023-DA-007. A copy of this material is attached hereto as Appendix D. A detail aid is a printed piece used by pharmaceutical sales representatives during in-person visits to physician offic

1. The study was funded by Penterra. Penterra provided full financial support for the Harmon et al. retrospective chart review, including funding for data collection, analysis, and the AHS poster presentation. This funding relationship was not disclosed anywhere in the detail aid.

2. The study lacked a control arm. The Harmon et al. retrospective chart review was a single-arm, uncontrolled study that reviewed medical records of patients treated with Zelvara® in clinical practice. Without a control arm, the study could not establish causation, rule out confounding variables, or provide a basis for comparative-effectiveness conclusions. B. Failure to Disclose Funding Source and Study Limitations

VI. Aggregate Risk Assessment A. Likelihood of Warning Letter vs. Untitled Letter Having analyzed each of the three cited promotional materials individually, we now assess the aggregate risk presented by the Inquiry and the totality of our investigative findings. The question of whether OPDP will issue a Warning Letter, an Untitled Letter, or resolve the matter informally will depend on multiple factors, including th